24 research outputs found
Die Funktion von Cyclin E und Skp2 in der Regulation der Proliferation und genetischen Instabilität in Hepatozyten der Maus : Endoreduplikation versus genomische Instabilität
[no abstract
Low Energy Electron Irradiation Is a Potent Alternative to Gamma Irradiation for the Inactivation of (CAR-)NK-92 Cells in ATMP Manufacturing
Background: With increasing clinical use of NK-92 cells and their CAR-modified
derivatives in cancer immunotherapy, there is a growing demand for efficient
production processes of these “off-the-shelf” therapeutics. In order to ensure safety
and prevent the occurrence of secondary tumors, (CAR-)NK-92 cell proliferation has to be
inactivated before transfusion. This is commonly achieved by gamma irradiation. Recently,
we showed proof of concept that low energy electron irradiation (LEEI) is a new method for
NK-92 inactivation. LEEI has several advantages over gamma irradiation, including a faster
reaction time, a more reproducible dose rate and much less requirements on radiation
shielding. Here, LEEI was further evaluated as a promising alternative to gamma irradiation
yielding cells with highly maintained cytotoxic effector function.
Methods: Effectiveness and efficiency of LEEI and gamma irradiation were analyzed using
NK-92 and CD123-directed CAR-NK-92 cells. LEE-irradiated cells were extensively
characterized and compared to gamma-irradiated cells via flow cytometry, cytotoxicity
assays, and comet assays, amongst others.
Results: Our results show that both irradiation methods caused a progressive decrease
in cell viability and are, therefore, suitable for inhibition of cell proliferation. Notably, the NKmediated
specific lysis of tumor cells was maintained at stable levels for three days postirradiation,
with a trend towards higher activities after LEEI treatment as compared to
gamma irradiation. Both gamma irradiation as well as LEEI led to substantial DNA damage
and an accumulation of irradiated cells in the G2/M cell cycle phases. In addition,
transcriptomic analysis of irradiated cells revealed approximately 12-fold more
differentially expressed genes two hours after gamma irradiation, compared to LEEI.
Analysis of surface molecules revealed an irradiation-induced decrease in surface
expression of CD56, but no changes in the levels of the activating receptors NKp46,
NKG2D, or NKp30.
Conclusions: The presented data show that LEEI inactivates (CAR-)NK-92 cells as
efficiently as gamma irradiation, but with less impact on the overall gene expression. Due
to logistic advantages, LEEI might provide a superior alternative for the manufacture of
(CAR-)NK-92 cells for clinical application
p27kip1: a target for tumor therapies?
The cyclin kinase inhibitor p27(kip1 )acts as a potent tumor supressor protein in a variety of human cancers. Its expression levels correlate closely with the overall prognosis of the affected patient and often predict the outcome to different treatment modalities. In contrast to other tumor suppressor proteins p27 expression levels in tumor cells are frequently regulated by ubiquitin dependent proteolysis. Re-expression of p27 in cancer cells therefore does not require gene therapy but can be achieved by interfering with the protein turnover machinery. In this review we will summarize experimental results which highlight the potential use of p27 as a target for oncological therapies
Constitutive Turnover of Cyclin E by Cul3 Maintains Quiescenceâ–ż â€
Two distinct pathways for the degradation of mammalian cyclin E have previously been described. One pathway is induced by cyclin E phosphorylation and is dependent on the Cul1/Fbw7-based E3 ligase. The other pathway is dependent on the Cul3-based E3 ligase, but the mechanistic details of this pathway have yet to be elucidated. To establish the role of Cul3 in the degradation of cyclin E in vivo, we created a conditional knockout of the Cul3 gene in mice. Interestingly, the biallelic loss of Cul3 in primary fibroblasts derived from these mice results in increased cyclin E expression and reduced cell viability, paralleling the loss of Cul3 protein expression. Cell cycle analysis of viable, Cul3 hypomorphic cells shows that decreasing the levels of Cul3 increases both cyclin E protein levels and the number of cells in S phase. In order to examine the role of Cul3 in an in vivo setting, we determined the effect of deletion of the Cul3 gene in liver. This gene deletion resulted in a dramatic increase in cyclin E levels as well as an increase in cell size and ploidy. The results we report here show that the constitutive degradation pathway for cyclin E that is regulated by the Cul3-based E3 ligase is essential to maintain quiescence in mammalian cells
Inhibition of hedgehog signaling attenuates carcinogenesis in vitro and increases necrosis of cholangiocellular carcinoma
Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers
Hepatobiliary and pancreatic cancers along with other gastrointestinal malignancies remain the leading cause of cancer-related deaths worldwide. Strategies developed in the recent years on immunotherapy and cancer vaccines in the setting of primary liver cancer as well as in pancreatic cancer are the scope of this review. Significance of orthotopic and autochthonous animal models which mimic and/or closely reflect human malignancies allowing for a prompt and trustworthy analysis of new therapeutics is underlined. Combinational approaches that on one hand, specifically target a defined cancer-driving pathway, and on the other hand, restore the functions of immune cells, which effector functions are often suppressed by a tumor milieu, are shown to have the strongest perspectives and future directions. Among combinational immunotherapeutic approaches a personalized- and individual cancer case-based therapy is of special importance
Skp2-dependent degradation of p27kip1 is essential for cell cycle progression
The activity of the SCF(skp2) E3 ligase is required for the proteolytic turnover of several proteins involved in cell cycle control and transcriptional regulation. Loss of skp2 in the mouse leads to a complex phenotype including changes in cell size and DNA content as well as severe proliferation defects. Here we show that the loss of a single skp2 substrate, namely, the cyclin kinase inhibitor p27kip1, reverts the phenotype of skp2 knockout hepatocytes to normal. By comparing the kinetics of p27 turnover and cell cycle progression in skp2 knockout and p27T187A knock-in mice, we define a short period in G1 in which p27 is able to block the cell cycle after the exit from quiescence. Loss of p27 turnover during this period prevents mitotic division and instead leads to compensatory cell growth
Epithelial mesenchymal transition and pancreatic tumor initiating CD44+/EpCAM+ cells are inhibited by Îł-secretase inhibitor IX.
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with a high rate of metastasis. Recent studies have indicated that the Notch signalling pathway is important in PDAC initiation and maintenance, although the specific cell biological roles of the pathway remain to be established. Here we sought to examine this question in established pancreatic cancer cell lines using the Îł-secretase inhibitor IX (GSI IX) to inactivate Notch. Based on the known roles of Notch in development and stem cell biology, we focused on effects on epithelial mesenchymal transition (EMT) and on pancreatic tumor initiating CD44+/EpCAM+ cells. We analyzed the effect of the GSI IX on growth and epithelial plasticity of human pancreatic cancer cell lines, and on the tumorigenicity of pancreatic tumor initiating CD44+/EpCAM+ cells. Notably, apoptosis was induced after GSI IX treatment and EMT markers were selectively targeted. Furthermore, under GSI IX treatment, decline in the growth of pancreatic tumor initiating CD44+/EpCAM+ cells was observed in vitro and in a xenograft mouse model. This study demonstrates a central role of Notch signalling pathway in pancreatic cancer pathogenesis and identifies an effective approach to inhibit selectively EMT and suppress tumorigenesis by eliminating pancreatic tumor initiating CD44+/EpCAM+ cells